Stay updated with breaking news from Compugen. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Correctly identifying cytokine pathways that are dysregulated in any given rheumatology patient could lead to better use of current biologic therapies, said a presenter at the 2022 Association of Women in Rheumatology annual conference.
The Israeli company has survived 30 years without revenue and still believes it has a prosperous future in cancer immunotherapies.
/PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, announced today...
Prioritized two indications, MSS-CRC and NSCLC, utilizing fully owned assets, COM701 and COM902 Focus on MSS-CRC and NSCLC expected to provide highest...
Going back to 1947, stocks have averaged gains of nearly 25% in the 12 months following technical recession confirmations. It's time to buy.